论文部分内容阅读
骨髓增生异常综合征(MDS)是一组异质性疾病。为预测其自然病程和不同治疗的结果,作者研究了治疗前各变量与小剂量阿糖胞苷(Ara-C)疗效间的关系。收集1984年2月至1989年5月间102例患者,MDS79例(包括难治性贫血7例,铁粒幼细胞性贫血3例,原始细胞增多的难治性贫血49例,慢性粒-单细胞白血病5例,原始细胞增多的难治性贫血转化型15例)和MDS转变的急性白血病(MDS-AML)23例。中位年龄72岁(47～86岁)。对所有患者观察至死亡或至少进入研究后6个月。小剂量Ara-C始量15mg/m~2·d,如服8周后无效,则增至25mg/m~2·d,继续治疗8周,仍无效或已获临
Myelodysplastic syndrome (MDS) is a heterogeneous group of diseases. To predict its natural history and outcome of different treatments, the authors studied the relationship between pretreatment variables and the efficacy of low-dose cytarabine (Ara-C). A total of 102 patients with MDS were collected from February 1984 to May 1989, including 79 cases of MDS (including 7 cases of refractory anemia, 3 cases of erythroblastic anemia, 49 cases of refractory anemia with primitive cells, 5 cases of leukemia, 15 cases of refractory anemia with an increase of blasts) and 23 cases of MDS-transformed acute leukemia (MDS-AML). The median age of 72 years (47 to 86 years old). All patients were observed for death or at least 6 months after entry into the study. Small doses of Ara-C starting amount of 15mg / m ~ 2 · d, if taken after 8 weeks of invalidity, then increased to 25mg / m ~ 2 · d, continue treatment for 8 weeks, still invalid or has been